DelveInsight’s “Perivascular epithelioid cell neoplasm – Market Insights, Epidemiology and Market Forecast – 2032“ report delivers an in-depth understanding of the Perivascular Epitheliod Cell Neoplasm, epidemiology insights, Perivascular Epitheliod Cell Neoplasm market trends, therapies and key companies working in the Perivascular Epitheliod Cell Neoplasm Market in the 7MM.
Perivascular Epithelioid Cell Neoplasm Overview
A family of rare tumors that form in the soft tissues of the stomach, intestines, lungs, female reproductive organs, and genitourinary organs. Most Perivascular Epithelioid Cell Neoplasm s are benign (not cancer). They often occur in children with an inherited condition called tuberous sclerosis. Also called a perivascular epithelioid cell tumor.
Perivascular Epithelioid Cell Neoplasm Epidemiology Insights
The total number of Perivascular Epithelioid Cell Neoplasm incident cases in the United States was around 250 cases in 2022 and is projected to increase during the forecasted period (2023-2032).
The United States contributed to the largest incident population of Perivascular Epithelioid Cell Neoplasm, acquiring ~64% of the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 28% and 8% of the total population share, respectively, in 2022.
Among the EU4 countries, Germany accounted for the largest number of Perivascular Epithelioid Cell Neoplasm cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
According to DelveInsight estimates, there were around 150 patients in the benign stage and less than 100 patients with malignant Perivascular Epithelioid Cell Neoplasm in the United States in 2022. The incidence is projected to increase during the forecasted period.
In 7MM, approximately 70% of the patient share is attributed to females, whereas only 30% of males suffer from Perivascular Epithelioid Cell Neoplasm.
Click here to learn more about the Perivascular Epithelioid Cell Neoplasm Market Landscape
The Report Covers the Perivascular Epithelioid Cell Neoplasm Epidemiology Segmented by:
Total Perivascular Epithelioid Cell Neoplasm prevalent cases
Total Perivascular Epithelioid Cell Neoplasm type-specific prevalent cases
Total Perivascular Epithelioid Cell Neoplasm diagnosed cases
Total Perivascular Epithelioid Cell Neoplasm treatable cases
Perivascular Epithelioid Cell Neoplasm Market Outlook
Key Companies Working in the Perivascular Epithelioid Cell Neoplasm Market
Aadi Bioscience
Sarcoma Oncology Research Center LLC,
Novartis Pharmaceuticals
CENTOGENE GmbH Rostock
Antia Therapeutics AG,
And many others
Perivascular Epithelioid Cell Neoplasm Therapies Covered and Analyzed in the Report
Nab-Sirolimus
BEZ235
Trabectedin
Everolimus
RAAD001
Learn more about the Key Companies and Emerging Therapies in the Perivascular Epithelioid Cell Neoplasm Market
Table of Contents
Key Insights
Perivascular Epithelioid Cell Neoplasm Introduction
Executive Summary of Perivascular Epithelioid Cell Neoplasm
Disease Background and Overview
Epidemiology and patient population
Perivascular Epithelioid Cell Neoplasm Emerging Therapies
Perivascular Epithelioid Cell Neoplasm Market Access and Reimbursement of Therapies
Perivascular Epithelioid Cell Neoplasm Market Drivers
Perivascular Epithelioid Cell Neoplasm Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Perivascular Epithelioid Cell Neoplasm Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services